Royalty Pharma earnings were $1.0B for the trailing 12 months ending Jun 30, 2025, with 53% growth year over year. The latest RPRX earnings report on Jun 30, 2025 announced Q2 2025 earnings of $30.2M, down 87.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RPRX reported annual earnings of $859.0M, with -24.3% growth.
RPRX past earnings growth
How has RPRX's earnings growth performed historically?
On RPRX's earnings call on Invalid Date, Royalty Pharma (NASDAQ: RPRX) reported Q2 2025 earnings per share (EPS) of $0.07, up 69.57% year over year. Total RPRX earnings for the quarter were $30.18 million. In the same quarter last year, Royalty Pharma's earnings per share (EPS) was $0.23.
As of the last Royalty Pharma earnings report, Royalty Pharma is currently profitable. Royalty Pharma's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $1.02 billion, a 51.61% increase year over year.
What was RPRX's earnings growth in the past year?
As of Royalty Pharma's earnings date in Invalid Date, Royalty Pharma's earnings has grown 52.98% year over year. This is 21.65 percentage points higher than the US Biotechnology industry earnings growth rate of 31.33%. RPRX earnings in the past year totalled $1.02 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.